Desensitization for solid organ and hematopoietic stem cell transplantation

Immunological Reviews

Volumn 258, Issue 1, 2014, Pages 183-207

  Zachary, Andrea A ^a   Leffell, Mary S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Desensitization; Donor specific antibodies; Hematopoietic stem cell transplantation; Intravenous immunoglobulin; Plasmapheresis; Solid organ transplantation

Indexed keywords

HLA ANTIBODY; IMMUNOGLOBULIN; ALLOANTIBODY; HLA ANTIGEN;

BLOOD GROUP ABO INCOMPATIBILITY; DESENSITIZATION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOADSORPTION; NONHUMAN; ORGAN TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SOLID ORGAN TRANSPLANTATION; ADVERSE EFFECTS; ANIMAL; BLOOD; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; PROCEDURES; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

ANIMALS; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; ISOANTIBODIES; ORGAN TRANSPLANTATION; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 84893611319     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12150     Document Type: Review

References (189)

1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2011 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2012. The data and analyses reported in the 2011 Annual Data Report of the Organ Procurement and Transplantation Network and the US Scientific Registry of Transplant Recipients have been supplied by the Minneapolis Medical Research Foundation and UNOS under contract with HHS/HRSA. The authors alone are responsible for reporting and interpreting these data; the views expressed herein are those of the authors and not necessarily those of the US Government.
2. OPTN data as of September 20, 2013 for patients listed and transplanted between 2001-2002; 2013. Available from http://optn.transplant.hrsa.gov.
3. Leffell MS, Steinberg AG, Bias WB, Machan CH, Zachary AA. The distribution of HLA antigens and phenotypes among donors and patients in the UNOS registry. Transplantation 1994;58:1119-1130.
4. Zachary AA, Steinberg AG, Bias WB, Leffell MS. The frequencies of HLA alleles and haplotypes and their distribution among donors and renal patients in the UNOS registry. Transplantation 1996;62:272-283.
5. 2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994-2003. Department of Health and Human Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI.
6. Zachary AA, Braun WE. Calculation of a predictive value for transplantation. Transplantation 1985;39:316-318.
7. National Organ Transplantation Act of 1984. Public Law 98-507, 98 Stat. 2339-2348 (Oct. 19, 1984).
8. Mjörnstedt L, Konar J, Nyberg G, Olausson M, Sandberg L, Karlberg I. Renal transplantation in patients with lymphocytotoxic antibodies: a 5 year experience from a single centre. Transplant Proc 1992;24:333-334.
9. Zhou YC, Cecka JM. Sensitization in renal transplantation. In: Terasak PI, Cecka JM eds. Clinical Transplants 1991. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1991:313-323.
10. Süsal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002;73:1269-1273.
11. Kerman RH, et al. AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival. Transplantation 1991;51:316-320.
12. Martin S, Liggett H, Robson A, Connolly J, Johnson RW. The association between a positive T and B cell flow cytometry crossmatch and renal transplant failure. Transplant Immunol 1993;1:270-276.
13. Cook DJ, Terasaki PI, Iwaki Y, Terashita GY, Lau MR. An approach to reducing early kidney transplant failure by flow cytometry crossmatching. In: Terasak PI ed. Clinical Transplants 1987. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1987:253-256.
14. Mahoney RJ, et al. The flow cytometric crossmatch and early renal transplant loss. Transplantation 1990;49:527-535.
15. Taylor CJ, Chapman JR, Ting A, Morris PJ. Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Transplantation 1989;48:953-958.
16. Karuppan S, Ohlman S, Möller E. The occurrence of cytotoxic and non-complement-fixing antibodies in the crossmatch serum of a patient with early acute rejection episodes. Transplantation 1992;54:839-844.
17. Karuppan SS, Lindholm A, Möller E. Fewer acute rejection episodes and improved outcome in kidney-transplanted patients with selection criteria based on crossmatching. Transplantation 1992;53:666-673.
18. Süsal C, Opelz G. Impact of HLA matching and HLA antibodies in organ transplantation: a collaborative transplant study view. Methods Mol Biol 2012;883:267-277.
19. Papassavas AC, Iniotaki-Theodorak A, Boletis J, Kostakis A, Stavropoulos-Giokas C. Epitope analysis of HLA class I donor specific antibodies in sensitized renal transplant recipients. Transplantation 2000;70:323-327.
20. McCluskey J, et al. Determinant spreading: lessons from animal models and human disease. Immunol Rev 1998;111:365-371.
21. Zachary AA, Vega RM, Lucas DP, Leffell MS. HLA antibody detection and characterization by solid phase immunoassays: methods and pitfalls. Methods Mol Biol 2012;882:289-308.
22. Rydberg L. ABO-incompatibility in solid organ transplantation. Transfusion Med 2001;11:325-342.
23. Gordon RD, Iwatsuki S, Esquivel CO, Tzakis A, Todo S, Starzl TE. Liver transplantation across ABO blood groups. Surgery 1986;100:342-348.
24. Cardella CJ, Pei Y, Brady HR. ABO blood group incompatible kidney transplantation: a case report and review of the literature. Clin Nephrol 1987;28:295-299.
25. Bensinger WI. Plasma exchange and immunoadsorption for removal of antibodies prior to ABO incompatible bone marrow transplant. Artif Organs 1981;5:254-258.
26. Falk JA, Cardella CJ, Halloran PF, Bear RA, Arbus GS. Graft outcome in the multiple transplant patient with a positive donor cross-match with non-current sera. Transplant Proc 1987;19:721-722.
27. Goeken NE. Outcome of renal transplantation following a positive cross-match with historical sera: the ASHI survey. Hum Immunol 1985;14:77-85.
28. Alarabi A, Backman U, Wikström B, Sjöberg O, Tufveson G. Plasmapheresis in HLA -immunosensitized patients prior to kidney transplantation. Int J Artif Organs 1997;20:51-56.
29. Miura S, Okazaki H, Sato T, Amada N, Terashima T. Beneficial effects of double-filtration plasmapheresis on living related donor renal transplantation in presensitized recipients. Transplant Proc 1995;27:1040-1041.
30. Palmer A, Welsh K, Gjorstrup P, Taube D, Bewick M, Thick M. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989;1:10-12.
31. Hakim RM, Milford E, Himmelfarb J, Wingard R, Lazarus JM, Watt RM. Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am J Kidney Dis 1990;16:423-431.
32. Mainra R, Xu Q, Chibbar R, Hassan A, Shoker A. Severe antibody-mediated rejection following IVIG infusion in a kidney transplant recipient with BK-virus nephropathy. Transplant Immunol 2013;28:145-147.
33. Glotz D, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993;56:335-337.
34. Glotz D, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002;2:758-760.
35. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994;57:553-562.
36. Jordan SC, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003;27:631-636.
37. Jordan SC, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly-HLA sensitized adult patients with end stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004;15:3256-3262.
38. Vo AA. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010;89:1095-1102.
39. Jordan SC, et al. Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation. Transplant Proc 2012;44:60-61.
40. Koslowski T, Andreoni K. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Ann Transplant 2011;16:19-25.
41. Alashkar N, et al. 10. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012;94:165-171.
42. Singer AL, Alachkar N, Montgomery RA, Zachary AA. Reply to "Defining the benefits of desensitization therapy". Transplantation 2013;95:e33.
43. Jordan S. IVIG vs. plasmapheresis for desensitization: which is better? Am J Transplant 2006;6:1510-1511.
44. Vo A, et al. Safety and adverse event profiles of IVIG products used for immunomodulation: a single center experience. Clin J Am Soc Nephrol 2006;1:844-852.
45. th International HLA and immunogenetics workshop: report on understanding antibodies in transplantation. Tissue Antigens 2007;69(Suppl):160-173.
46. Kahwaji J, et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011;6:2894-2900.
47. Stoclin A, et al. Transfusion-related acute lung injury after intravenous immunoglobulin treatment in a lung transplant recipient. Vox Sang 2013;104:175-178.
48. Vo AA, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 2013;95:852-858.
49. Appel JZ, Hartwig MG, Davis RD, Reinsmoen NL. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Hum Immunol 2005;66:378-386.
50. Billing H, et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008;86:1214-1221.
51. Moger V, et al. Intravenous immunoglobulin: a safe option for treatment of steroid-resistant rejection in the presence of infection. Transplantation 2004;77:1455-1456.
52. Tanriover B, et al. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. Transplant Proc 2008;40:3393-3396.
53. John R, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation. Circulation 1999;100(Suppl):11229-11235.
54. Montgomery RA, Zachary A. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004;8:535-542.
55. Furth S, Neu AM, Hart J, Zachary A, Colombani P, Fivush BA. Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report. Pediatr Transplant 1999;3:146-149.
56. Montgomery RA, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000;70:887-895.
57. Zachary AA, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003;76:1519-1525.
58. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005;66:364-370.
59. Gloor J, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003;3:1017-1023.
60. Gloor JM, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004;78:221-227.
61. Jordan SC, Vo AA, Tyan D, Nast CC, Toyoda M. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005;9:408-415.
62. Rodríguez Ferrero M, Rincón A, Bucalo L, Rementería A, Anaya F. Treatment of acute antibody-mediated rejection: a single-center experience. Transplant Proc 2010;42:2848-2850.
63. Slatinska J, Honsova E, Burgelova M, Slavcev A, Viklicky O. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience. Ther Apher Dial 2009;13:108-112.
64. Bierl C. Antibody-mediated rejection in heart transplant recipients: potential efficacy of B-cell depletion and antibody removal. In: Terasaki PI ed. Clinical Transplants 2006. Los Angeles, CA: UCLA Tissue Typing Laboratory, 2006:489-496.
65. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006;6:346-351.
66. Tanabe K. Japanese experience of ABO-incompatible living kidney transplantation. Transplantation 2007;84(Suppl 1):S4-S7.
67. Genberg H, Kumlien G, Wennberg L, Tydén G. Long-term results of ABO-incompatible kidney transplantation with antigen-specific immunoadsorption and rituximab. Transplantation 2007;84(Suppl):S44-S47.
68. Montgomery RA, et al. ABO incompatible renal transplantation: a paradigm read for broad implementation. Transplantation 2009;87:1246-1255.
69. Montgomery RA, et al. Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. In: Cecka JM, Terasaki PI eds. Clinical Transplants 2003. Los Angeles, CA: UCLA Tissue Typing Laboratory, 2003:199-213.
70. Uchida J, et al. Desensitization protocol in highly HLA-sensitized and ABO-incompatible high titer kidney transplantation. Transplant Proc 2010;42:3998-4002.
71. Al Meshari K. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients. Transplant Proc 2013;45:1423-1426.
72. Perry DK, et al. Proteosome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009;9:201-209.
73. Lonze BE, et al. The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib. In: Cecka JM, Terasaki PI eds. Clinical Transplants 2009. Los Angeles, CA: UCLA Tissue Typing Laboratory, 2009:377-384.
74. Bhimaraj A, Taylor DO. How to deal with presensitized candidates for heart transplantation? Curr Opin Organ Transplant 2011;16:529-535.
75. Guthoff M, Schmid-Horch B, Weisel KC, Häring HU, Königsrainer A, Heyne N. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl Immunol 2012;26:171-175.
76. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant 2011;30:1320-1326.
77. Stegall MD, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011;11:2405-2413.
78. Zachary AA, Kopchaliiska D, Montgomery RA, Leffell MS. HLA-specific B cells. I. A method for their detection, quantification, and isolation using HLA tetramers. Transplantation 2007;83:982-988.
79. Zachary AA, Kopchaliiska D, Montgomery RA, Melancon JK, Leffell MS. HLA-specific B cells. II. Application to transplantation. Transplantation 2007;83:989-994.
80. Zachary AA, Lucas DP, Montgomery RA, Leffell MS. Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. Transplantation 2013;95:701-704.
81. Jin MK, et al. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Transplant Proc 2012;44:200-203.
82. Gabardi S, Townsend K, Martin ST, Chandraker A. Evaluating the impact of pre-transplant desensitization utilizing a plasmapheresis and low-dose intravenous immunoglobulin protocol on BK viremia in renal transplant recipients. Transpl Infect Dis 2013;15:361-368.
83. Warren DS, Montgomery RA. Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange. Immunol Res 2010;47:257-264.
84. Bentall A, et al. Five year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013;13:76-85.
85. Thielke JJ, et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009;87:268-273.
86. Montgomery RA, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011;365:318-326.
87. Reinsmoen NL, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008;86:820-825.
88. Gloor JM, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010;10:582-589.
89. Klein K, et al. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Ather Suppl 2013;14:199-202.
90. Hirai T, Kohei N, Omoto K, Ishida H, Tanabe K. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection. Transpl Int 2012;25:925-934.
91. Yamanaga S, et al. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches. Hum Immunol 2013;74:1111-1118.
92. Kraus ES, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009;9:1826-1834.
93. Genberg H, Kumlien G, Wennberg L, Tydén G. Isoagglutinin adsorption in ABO-incompatible transplantation. Transfus Apher Soi 2010;43:231-235.
94. Montgomery JR, Berger JC, Warren DS, James NT, Montgomery RA, Segev DL. Outcomes of ABO-incompatible kidney transplantation in the United States. Transplantation 2012;93:603-609.
95. Takahashi K, Saito K. ABO-incompatible kidney transplantation. Transplant Rev 2013;27:1-8.
96. Fuchinoue S, et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011;91:853-857.
97. Crew RJ, Ratner LE. ABO-incompatible kidney transplantation: current practice and the decade ahead. Curr Opin Organ Transplant 2010;15:526-530.
98. Gloor JM, et al. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005;80:1572-1577.
99. Toki D, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant 2009;9:567-577.
100. Uchida J, et al. Excellent outcomes of ABO-incompatible kidney transplantation: a single-center experience. Transplant Proc 2012;44:204-209.
101. Tobian AA, et al. ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 2010;10:1247-1253.
102. Sanada Y, et al. Role of apheresis and dialysis in pediatric living donor liver transplantation: a single center retrospective study. Ther Apher Dial 2012;16:368-375.
103. Song GW, et al. Successful experiences of ABO-incompatible adult living donor liver transplantation in a single institute: no immunological failure in 10 consecutive cases. Transplant Proc 2013;45:272-275.
104. Raut V, Uemoto S. Management of ABO-incompatible living-donor liver transplantation: past and present trends. Surg Today 2011;41:317-322.
105. West LJ. B-cell Tolerance following ABO-incompatible infant heart transplantation. Transplantation 2006;81:301-307.
106. Irving C, Gennery A, Kirk R. Pushing the boundaries: the current status of ABO-incompatible cardiac transplantation. J Heart Lung Transplant 2012;31:791-796.
107. Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 2009;42:553-560.
108. Jordan SC, Toyoda M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol 2011;7:341-348.
109. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013;13:176-189.
110. Leffell MS, et al. Effect of induction agent on cellular and humoral responses to renal transplants in sensitized. Am J Transplant 2008;8(s2):182.
111. Locke JE, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009;9:2136-2139.
112. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004;34:2303-2312.
113. Iwasaki K, Miwa Y, Haneda M, Uchida K, Nakao A, Kobayashi T. Significance of HLA class I antibody-induced antioxidant gene expression for endothelial cell protection against complement attack. Biochem Biophys Res Commun 2010;391:1210-1215.
114. Jin YP, et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 2004;65:291-302.
115. Jindra PT, Jin YP, Rozengurt E, Reed EF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008;180:2357-2366.
116. Li F, Zhang X, Jin YP, Mulder A, Reed EF. Antibody ligation of human leukocyte antigen class I molecules stimulates migration and proliferation of smooth muscle cells in a focal adhesion kinase-dependent manner. Hum Immunol 2011;72:1150-1159.
117. Tha-In T, Metselaar HJ, Bushell AR, Kwekkeboom J, Wood KJ. Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells. Transplantation 2010;89:1446-1455.
118. Sharma KG, et al. Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transpl Immunol 2010;23:117-120.
119. Tjon ASW, et al. Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells. Clin Exper Immunol 2013;173:259-267.
120. Chien PJ, Yeh JH, Shih CM, Hsueh YM, Chen MC, Chiu HC. A decrease in the percentage of CD3+ cells is correlated with clinical improvement during plasmapheresis in patients with myasthenia gravis. Artif Organs 2013;37:211-216.
121. Kiprov DD, Dau PC, Morand P. The effect of plamapheresis and drug immunosuppression on T-cell subsets as defined by monoclonal antibodies. J Clin Apher 1983;1:57-63.
122. Sadeghi M, et al. Plasmapheresis adjust inflammatory responses in potential kidney transplant recipients. Transplantation 2013;95:1021-1029.
123. Krystufkova E, Sekerkova A, Striz I, Brabcova I, Girmanova E, Viklicky O. Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy. Nephrol Dial Transplant 2012;27:2576-2582.
124. Mohiuddin MM, Ogawa H, Yin DP, Shen J, Galili U. Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen. Transplantation 2003;75:258-262.
125. Takahashi K. Accommodation in abo-incompatible kidney transplantation: why do kidney grafts survive? Transplant Proc 2004;36:S193-S196.
126. Tanabe T, Ishida H, Horita S, Yamaguchi Y, Toma H, Tanabe K. Decrease of blood type antigenicity over the long-term after ABO-incompatible kidney transplantation. Transpl Immunol 2011;25:1-6.
127. Aikawa A, et al. Clinical outcome and accommodation in ABO incompatible kidney transplantation. In: Cecka JM, Terasaki PI eds. Clinical Transplants 2004. Los Angeles, CA: UCLA Tissue Typing Laboratory, 2004:135-142.
128. West LJ. Targeting antibody-mediated rejection in the setting of ABO-incompatible infant heart transplantation: graft accommodation vs. B cell tolerance. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:223-232.
129. Locke JE, Zachary AA, Mohammed BS, Warren DS, Montgomery RA. Rescue splenectomy for severe acute antibody-mediated rejection. In: Terasaki PI ed. Clinical Transplants 2006. Los Angeles, CA: UCLA Tissue Typing Laboratory, 2006:518-520.
130. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012;30:221-241.
131. Zhang Q, Reed EF. Non-MHC antigenic targets of the humoral immune response in transplantation. Curr Opin Immunol 2010;22:682-688.
132. Dragun D, Catar R, Phillippe A. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr Opin Organ Transplant 2013;18:430-435.
133. Jackson AM, Kuperman MB, Montgomery RA. Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. Am J Transplant 2012;12:1643-1649.
134. Eng H, Montgomery R, Leffell M, Zachary A. Effect of plasmapheresis on angiotensin II type 1 receptor antibody. Am J Transplant 2013;13:207.
135. Gyurkocza B, Rezvani A, Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol 2010;3:285-299.
136. Li H, Sykes M. Emerging concepts in hematopoietic cell transplantation. Nat Rev Immunol 2012;12:403-416.
137. Luznik L, O'Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncology 2012;39:683-693.
138. Fuchs E, O'Donnell PV, Brunstein CG. Alternative transplant donor sources: is there any consensus? Curr Opin Oncol 2013;25:173-179.
139. Ciurea SO, Champlin RE. Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies. Biol Blood Marrow Transplant 2013;19:180-184.
140. Lee SJ, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110:4576-4583.
141. Hurley CK, et al. A high degree of disparity arises from limited allelic diversity: analysis of 1775 unrelated bone marrow transplant donor-recipient pairs. Hum Immunol 2007;68:30-40.
142. Cutler C, Ballen KK. Improving outcomes in umbilical cord blood transplantation: state of the art. Blood Rev 2012;26:241-246.
143. Luznik L, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641-650.
144. Munchel AT, Kasamon YL, Fuchs EJ. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. Best Pract Res Clin Haematol 2011;24:359-368.
145. Kasamon YL, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010;16:482-489.
146. Velardi A, Ruggeri L, Mancusi A. Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant. Curr Opin Hematol 2012;19:319-323.
147. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones R, Fuchs EJ. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010;16:533-542.
148. Petersdorf E. Genetics of graft-versus-host-disease: the major histocompatibility complex. Blood Rev 2013;27:1-12.
149. Johnston L. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. Best Pract Res Clin Hematol 2008;21:177-192.
150. Mattsson J, Ringdén O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008;14(S1):165-170.
151. Fancosi D, Zucca A, Scatena F. The role of anti-HLA antibodies in hematopoietic stem cell transplantation. Biol Blood Marrow transplant 2011;17:1585-1588.
152. Yoshihara S, Taniguchi K, Ogawa H, Saji H. The role of HLA antibodies in allogeneic SCT: is the 'type-and-screen' strategy necessary not only for blood type but also for HLA? Bone Marrow Transplant 2012;47:1499-1506.
153. Brand A, Doxiadis IN, Roelen DL. On the role of HLA antibodies in hematopoietic stem cell transplantation. Tissue Antigens 2013;81:1-11.
154. Spellman S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010;115:2704-2708.
155. Ciurea SO, et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 2011;118:5957-5964.
156. Takanashi M, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010;116:2839-2846.
157. Brunstein CG, Noreen H, DeFor TE, Maurer D, Miller JS, Wagner JE. Anti-HLA antibodies in double umbilical cord blood transplantation. Biol Blood Marrow Transplant 2011;17:1704-1708.
158. Cutler C, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011;118:6691-6697.
159. Ansari M, et al. The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children. PLoS ONE 2013;8:e72141.
160. Ruggeri A, et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société Francaise de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis. Haematologica 2013;98:1154-1160.
161. Yoshihara S, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012;47:508-515.
162. Gladstone DE, et al. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant 2013;19:647-652.
163. Anasetti C, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989;320:197-204.
164. Ottinger HD, et al. Positive serum crossmatch as predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation. Transplantation 2002;73:1280-1285.
165. Ciurea SO. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 2009;88:1019-1024.
166. Leffell MS, et al. Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation. Tissue Antigens 2009;74:494-498.
167. Taylor PA, et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007;109:1307-1315.
168. Xu H, et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood 2006;108:3611-3619.
169. Levesque V, et al. B-cell-dependent memory T cells impede nonmyeloablative mixed chimerism induction in presensitized mice. Am J Transplant 2011;11:2322-2331.
170. Ishiyama K, Anzai N, Tashima M, Hayashi K, Saji H. Rapid hematopoietic recovery with high levels of DSA in an unmanipulated haploidentical transplant patient. Transplantation 2013;95:e76-e77.
171. Fernandez-Vina MA, de Lima M, Ciurea SO. Humoral sensitization matters in CBT outcome. Blood 2011;118:6482-6484.
172. Norlander A, Uhlin M, Ringden O, Kumlien G, Hausenberger D, Mattsson J. Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation. Transplant Immunol 2011;25:153-158.
173. Sniecinski IJ, O'Donnell MR. Hemolytic complications of hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ eds. Hematopoietic Cell Transplantation. 2nd edn. Malden, MA: Blackwell Science Inc, 1999:674-683.
174. Rowley SD. Hematopoietic stem cell transplantation between red cell incompatible donor-recipient pairs. Bone Marrow Transplant 2001;28:315-321.
175. Stussi G, Halter J, Schanz U, Seebach JD. ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation. Transfus Apher Sci 2006;35:59-69.
176. Keever-Taylor CA, et al. Analysis of risk factors for the development of GVHD after T-cell depleted allogeneic BMT: effect of HLA disparity. ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant 2001;7:620-630.
177. Remberger M, Watz E, Ringdén O, Mattsson J, Shanwell A, Wikman A. Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:675-682.
178. Blin N, et al. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant 2010;16:1315-1323.
179. Barge AJ, Johnson G, Witherspoon R, Torok-Storb B. Antibody-mediated marrow failure after bone marrow transplantation. Blood 1989;74:1477-1480.
180. Braun N, et al. Successful transplantation of highly selected CD34+ peripheral blood stem cells in a HLA-sensitized patient treated with immunoadsorption onto protein A. Transplantation 2000;69:1742-1744.
181. Pollack M, Ririe D. Clinical significance of recipient antibodies to stem cell donor mismatched class I HLA antigens. Hum Immunol 2004;65:245-247.
182. Costa LJ, Moussa O, Bray RA, Stuart RK. Overcoming HLA-DPB1 donor specific antibody-mediated hematopoietic graft failure. Br J Hematol 2010;151:84-109.
183. Maruta A, et al. Donor-HLA-incompatible marrow transplantation with an anti-donor cytotoxic antibody in the serum of the patient. Bone Marrow Transplant 1991;7:397-400.
184. Narimatsu H, et al. Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion. Bone Marrow Transplant 2005;36:555-556.
185. Yang YG, et al. Tolerization of anti-Galα1-3 Gal natural antibody-forming B cells by induction of mixed chimerism. J Exp Med 1998;187:1335-1342.
186. Ohdan H, Yang YG, Shimizu A, Swenson KG, Sykes M. Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Galα1, 3 Gal-mediated graft rejection. J Clin Invest 1999;104:281-290.
187. Ohdan H, Swenson KG, Kitamura H, Yang YG, Sykes M. Tolerization of Gal alpha 1, 3, Gal-reactive B cells in pre-sensitized alpha 1, 3-galactosyltransferase-deficient mice by nonmyeloablative induction of mixed chimerism. Xenotransplantation 2001;8:227-238.
188. Kawahara T, Shimizu I, Ohdan H, Zhao G, Sykes M. Differing mechanisms of early and late B cell hyporesponsiveness induced by mixed chimerism. Am J Transplant 2005;5:2821-2829.
189. Brodsky RA, Fuller AK, Ratner LE, Leffell MS, Jones RJ. Elimination of alloantibodies by immunoablative high-dose cyclophosphamide. Transplantation 2001;71:482-484.